Injection for Weight Loss: 2024 Peptide Market Trends & Brand Efficacy Analysis
Published: 12 7 月, 2026 23:47
Author: Stephanie Diaz
Abstract: The 2024 peptide injection market for weight loss is driven by GLP-1 agonists (semaglutide, tirzepatide) and emerging dual/triple agonists. Market data shows a 35% CAGR, with Novo Nordisk and Eli Lilly dominating 80% of branded sales. Compounded peptides offer cost savings but lack FDA approval, posing purity risks. Key selection criteria include third-party certificate of analysis (CoA), cold-chain logistics compliance, and GMP-certified manufacturing. Efficacy varies by peptide type: semaglutide yields 15% weight loss vs. 22% for tirzepatide. Industry trends emphasize regulatory tightening and personalized dosing protocols.